Polymorphisms of the ABCB1 (MDR1) and ABCG2 (BCRP) genes were reported to alter the expression and function of these drug transporters. Both proteins are present at the main pharmacokinetic barriers including the blood-brain barrier. Data from 291 children with acute lymphoblastic leukaemia were analysed in this retrospective study. ABCB1 3435T4C, 2677G4T/A, 1236C4T and ABCG2 421C4A, 34G4A genotypes were determined. Encephalopathy episodes were more frequent among those with ABCB1 3435TT genotype than in the 3435CC/CT group (odds ratio (OR) 3.5; P ¼ 0.03). Patients with the ABCG2 421A allele tended to have more complications than wild type homozygotes (OR ¼ 2.0; P ¼ 0.25). The rate of the adverse effect was similar in those harbouring no or only one of the predisposing genotypes, that is, either ABCB1 3435TT or ABCG2 421AA/AC. However, significantly more children suffered encephalopathy in the group with both predisposing genotypes (OR ¼ 12.3; P ¼ 0.005). In conclusion, these variations exert synergistic effect in predisposing patients to toxic neurological complications of chemotherapy.
Introduction
The body is defended against xenobiotics by active efflux transporters. Various sets of these transporters are localized at the barriers of the whole body (on absorptive surfaces and in organs for excretion) and at the border of the cells (in the plasma membrane). These two barriers sustain a double concentration gradient protecting our cells against toxic compounds. The most sensitive compartments, namely the central nervous system (CNS), the gonads and the foetus are surrounded by one more barrier, the blood-brain barrier, bloodcerebrospinal fluid (CSF) barrier, blood-testis barrier or the blood-placental barrier.
Members of the ATP-binding cassette (ABC) transporter family are thought to be important contributors to this defence mechanism. In this study, we focused on ABCB1 (also known as permeability glycoprotein or MDR1) and ABCG2 (BCRP, MXR). In humans, these are expressed at the apical membrane of the mucosal epithelium all along the gastrointestinal tract, at the biliary canalicular membrane of hepatocytes and on the apical surface of cells in the proximal kidney tubules (ABCG2 was not shown at this localization). In the CNS context, very high amounts of both transporters are found at the luminal surface of endothelium cells in the brain (blood-brain barrier) and at the basolateral membrane of the chorioid plexus epithelium (blood-CSF barrier). Neither of these transporters were found in human neurons or glial cells. [1] [2] [3] [4] [5] [6] The enormous relevance of the 'extra' barrier-the bloodbrain barrier-was clearly demonstrated in animal experiments. In Mdr1a knockout mice, the plasma concentration of its substrate digoxin was 1.9-fold higher compared with wild-type animals, while the brain concentration was increased 35-fold. It was also shown that the brain penetration is variably affected regarding different substrates of this transporter. 7 Interestingly, milder or no such alterations were observed with different substrates in Abcg2 knockout mice. 6, 8 Many antineoplastic agents are substrates of these proteins. Therefore, we hypothesized that constitutional differences in the activity of these transporters may play a role in neurological complications of anticancer therapy. There are single nucleotide polymorphisms (SNPs) in both human genes, which are considered to be functional. The ABCB1 3435T4C is a frequent exonic silent variation, which was shown to be associated with altered mRNA expression (decreased expression of the T allele was detected in Caucasians). 9 There are two leading theories for the mechanism of action. According to the first theory this SNP and other variations (2677G4T/A and 1236C4T) in linkage disequilibrium are linked to a putative functional polymorphism that causes the differences observed. 10 On the other hand it was shown that the 3435T mRNA is characterized by decreased stability, while the linked alleles themselves have no effect on gene expression. 11 The ABCG2 34G4A and 421C4A are rare non-synonymous polymorphisms resulting in V12M and Q141K variations. The one hundred and forty-first amino acid is localized to the ATPase domain of the transporter and the 141K allele was associated with decreased transport activity as well as lower protein expression. The twelfth amino acid is placed within the first transmembrane domain and the 12M allele may disturb the protein's proper membrane localization resulting in decreased cellular transport. 12, 13 Data on the functional relevance of these SNPs and the controversies have been reviewed recently by many authors. 14, 15 In order to assess the possible value of these SNPs in the prediction of neurotoxic side effects of chemotherapy, we have studied a large cohort of patients treated for childhood acute lymphoblastic leukaemia (ALL). Using this population has the following advantages: previous or accompanying diseases, which affect organs with implications in pharmacokinetics or the brain itself are very rare among children compared with the adult population in oncology. Furthermore, co-medication is unusual. ALL is the most frequent single histological entity in paediatric oncology, and is responsible for approximately one-fourth of the incidence of all malignancies under 14 years of age. 16, 17 Results
Study population and allele frequencies
We obtained blood or bone marrow samples from 291 ALL patients. This represents 53.4% of the whole population treated according to the same protocol arms in the same hospitals. Sixteen children were excluded from analyses. Exclusions have been made because of loss of clinical documentation (n ¼ 3), major deviations of chemotherapy protocol due to non-neurological complications (n ¼ 2), preceding chemotherapy due to another malignancy (n ¼ 1) and coexisting diseases with major impact on pharmacokinetics (n ¼ 1; congenital unilateral renal agenesis) or on the CNS (n ¼ 3; Down's syndrome). Six more patients were excluded due to non-completed chemotherapy protocol because of early death (three of them died during induction and there were three septic deaths later).
After exclusions, we analysed the data from 275 patients. The study population is in Hardy-Weinberg equilibrium regarding all five polymorphic sites (P440.05). Allele frequencies (indicated in Table 1 ) were similar to data from Caucasian populations published by other authors. 18, 19 Also in concordance with previous findings, we observed strong linkage disequilibrium among the examined ABCB1 SNPs, which contributed to two dominating haplotypes, 1236C-2677G-3435C (CGC) and 1236T-2677T-3435T (TTT).
Seventeen patients (6.2%) were classified as developing acute, toxic encephalopathy. Nine of these events occurred during induction and reinduction phase, seven during consolidation and nine during re-intensification. Four more patients developed CNS symptoms of grade III and above, but with obvious non-toxic causes: intracranial haemorrhage in one case, severe fluid electrolyte imbalance in one case and two patients with neurological signs in severe septic state with hypoxia or hypovolaemia. Among the 17 children with toxic encephalopathy, five had depressed level of consciousness, nine had seizures, eight patients developed palsies and two children had expressive aphasia of grade III or above according to CTCEA v3.0 criteria (http://ctep. info.nih.gov/reporting/index.html). These symptoms were reversible, with patients recovering fully within days or weeks. There was one exception; after a few days in coma, this child needed 1 year to recover from memory disorders and visual agnosia, and required long-term anticonvulsive therapy because of enduring focal epilepsy.
Occurrence of encephalopathy in relation to genotype Regarding the ABCB1 3435T4C SNP, patients with the TT genotype were more prone to acute, toxic encephalopathy than those in the CC þ CT group (odds ratio (OR) ¼ 2.6, confidence interval 95% 1.0-7.1 in univariate analysis, and OR ¼ 3.5, confidence interval 95% 1.2-10.7 in multivariate analysis) (see Figure 1) . Homozygosity for the related haplotype (TTT) was calculated to be less predictive and non-significant (OR ¼ 1.7, 0.6-5.1 and OR ¼ 2.2, 0.7-7.2 in ABCB1-ABCG2 interaction in toxic encephalopathy DJ Erdilyi et al univariate and multivariate analysis, respectively). As for ABCG2, patients harbouring at least one variant 421A allele tended to have somewhat more encephalopathy episodes than others (OR ¼ 2.1, 0.7-5.8 and 2.0, 0.6-6.1, respectively); however, this association was of no statistical significance ( Figure 1 ). Encephalopathy had not occurred among the 20 patients harbouring the rare ABCG2 34A allele, and therefore the OR could not be calculated. Furthermore, we examined the possible interaction between the ABCB1 3435T4C and ABCG2 421C4A variants. As shown in Table 2 , the stratified analyses revealed that the effect of these variants in the absence of the other variant is negligible; however, when both were present, the increase in risk was considerable (OR ¼ 12.3; confidence interval 95% 2.2-70.4 in multivariate analysis). The combined effect of these genes surpassed both the sum and the product of their separate effects. Formal evaluation of interaction revealed a statistically significant synergistic interaction even on a multiplicative scale (P ¼ 0.036).
We also performed analyses separately regarding certain parts of the therapy regimen. When comparing those harbouring neither predisposing genotypes with those harbouring both (ABCB1 3435TT with ABCG2 421AA/AC), the association was most prominent in the consolidation phase of the chemotherapy protocol (see Table 2 ). 
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Discussion
We studied the association of ABCB1 and ABCG2 gene variants with the acute CNS side effects of cytostatic therapy in 275 patients.
Patients with the ABCB1 3435TT genotype suffered significantly more acute, toxic encephalopathy episodes than 3435CC þ CT children (OR ¼ 3.5 in the multivariate test). The genotype defined by this SNP alone was more predictive for the adverse effect than the 3435T-2677T-1236T haplotype, with the latter showing a lower OR and proving to be statistically non-significant. When the ABCG2 421C4A SNP was analysed separately, it was not shown to be associated with the occurrence of encephalopathy, although with low statistical power and a tendency of higher adverse effect rate in those harbouring the variant 421A allele (OR ¼ 2.0). The clinical relevance of the ABCG2 34G4A variation could not be examined due to low variant allele frequency.
Analyses were also performed according to groups of combined genotype data, based on the most predictive ABCB1 and ABCG2 variations. Those with the ABCB1 3435TT genotype and also carrying the ABCG2 421A allele were more prone to toxic encephalopathy, compared with those with no or only one predisposing genotype. This difference is striking, since more than one-quarter of children suffered encephalopathy in the previous group, whereas the incidence varied between 2.5 and 5.9% in the latter ones. An OR of 12.3 was calculated in complication rate if genotype groups were combined (in patients with both ABCB1 3435TT and ABCG2 421AA þ AC versus those with ABCB1 3435CC þ CT and ABCG2 421CC). Results of interaction tests also suggest that the separate effects of these genotypes are attributable to their interaction only. This means that both transporters have to be impaired to allow toxicity.
Our results are consistent with the current knowledge on the localization and function of ABC transporters and with recent data suggesting that ABCB1 3435T4C and ABCG2 421C4A variations are functional as described in the introduction. 9, [12] [13] [14] [15] The results are also concordant with the findings of Wang et al. 11 who suggested that among linked ABCB1 SNPs, the 3435T4C silent variation is responsible for the differences in gene expression.
In the ALL Berlin-Münster-Frankfurt 90 and 95 protocols, the following antineoplastic drugs are known to be neurotoxic as well as to be substrates of the transporters: vincristine (substrate of ABCB1 only), doxorubicin (both), daunorubicin (both), MTX (both), prednisone (ABCB1) and dexamethasone (ABCB1). Dexamethasone is also an inducer of ABCB1, and in addition some glucocorticoids were shown to inhibit ABCG2. 6, 20 Cytostatic drugs in this list are directly neurotoxic and are able to cause seizures, irritability, confusion, lethargy, unconsciousness, myelitis, arachnitis, acute leukoencephalopathy or focal neurological symptoms, while the withdrawal of glucocorticoids may evoke cerebral oedema. 21, 22 We intended to identify a segment of the therapy regimen-and a corresponding group of drugs-being responsible for the associations. The largest differences were observed in the consolidation phase including MTX and mercaptopurine. Both ABCG2 and ABCB1 transport MTX, 23, 24 and therefore we examined the association of the SNPs with CSF MTX concentrations in a subgroup of patients. No difference was found among the examined genotype groups.
ABCB1 transports non-conjugated amphipathic compounds, while the substrates of ABCG2 are glucuronil or sulphate conjugates-in some cases the conjugated forms of the same drugs as ABCB1. 6, 20 It is important to note that many phase I and II drug-metabolizing enzymes-prerequisites of ABCG2 function-are expressed in the blood-brain barrier as well as in glial cells and neurons. [25] [26] [27] [28] A positive interaction of the two polymorphic genes could be explained by the transport of compounds by both transporters, based on some hypothetic cutoff intracellular drug concentrations. The two transporters may also have substrates with mutually complementing neurotoxic effects. The routes of metabolism and the intermediary metabolites of some cytostatic drugs are not yet fully discovered, although important new data are emerging nowadays, 29 and transport properties of possibly neurotoxic metabolites of chemotherapy agents are unexplored. Such metabolites might also play a role in the consequences of interindividual differences of efflux transporter activities. ABCB1 and ABCG2 also have physiologic substrates, altered transport of which might influence the sensitivity of CNS to neurotoxic agents.
The shortcomings of this study are as follows: our study population is potentially biased, as patients who died before our blood sample collection period are underrepresented (blood samples of living patients only partially complemented by smears due to difficulties in contacting parents for permissions). Out of the 291 patients from whom we have collected samples, 94% are alive. However, the estimated survival rate should have been 84%, calculated for the low-and medium-risk groups based on population data maintained at the Hungarian Paediatric Cancer Registry (www.gyerekdaganat.hu). Given the probably mild prognostic role of ABCB1 SNPs, 30, 31 it is rather unlikely that the loss of a relatively small proportion of patients could have explained the observed excess risk among those carrying both variants. Apart from this factor, sample selection is considered to be random. Although this study is among the largest ones published in paediatric pharmacogenetics, owing to the low prevalence of the rare alleles, the clinical relevance of ABCG2 variations and the issue of the genegene interaction could not be thoroughly evaluated. The high intra-and interpatient variability of the kinetic data render the statistical power of the CSF-MTX concentration analyses very low. 32 Finally, we argue against the statement that ABCB1 polymorphisms are not suitable for individualized ABCB1-ABCG2 interaction in toxic encephalopathy DJ Erdilyi et al chemotherapy due to the large variability of gene expression unexplainable by the polymorphisms alone. 10 Due to the hierarchic concentration gradients with multiplicative effect and the repeated and combined administration of toxic substrate drugs, the impact of minor differences in transporter functions might be remarkable. Survival analysis cannot be performed on our sample set due to the bias related to retrospective sample collection. In another study, the ABCB1 3435T allele was associated with higher occurrence of CNS relapse in children treated with the same chemotherapy protocol as our patients. 33 These findings warrant future chemotherapy individualization. For a large number of patients with good drug-transport properties, the current therapy is safe but insufficient. Drug doses could be increased because they are the patients who are less sensitive to toxicities. On the other hand unnecessary and highly toxic doses are applied to those few children with weaker barriers. The associations underlying this concept have to be confirmed and refined in studies on larger cohorts, and the substrate drugs examined separately. If so, the way to find the optimal doses of cytostatic drugs for intracranial tumours could be straightforward. However, therapy individualization is probably more difficult in case of systemic diseases like leukaemia, because of the different pharmacokinetic effects of transporter polymorphisms regarding numerous important compartments (bone marrow, CNS, testes and so on).
In conclusion, toxic encephalopathy episodes were more frequent among children of ABCB1 3435TT genotype than in the 3435CC þ CT group. This SNP was found to be a better predictor of this neurotoxic complication than the 3435T-2677T-1236T haplotype. Merely a tendency of higher complication rate was shown among those harbouring ABCG2 421A allele when analysed separately. However, if examined in combination with the ABCB1 3435T4C variation, striking differences were shown among genotype groups, and a synergistic gene-gene interaction was demonstrated. We think that these phenomena may have considerable impact on future therapy individualization.
Materials and methods
Study population and definitions
In a retrospective manner, DNA was obtained from 291 children who underwent chemotherapy due to ALL. Patients were diagnosed with ALL between 1990 and 2002, aged 1-18 years at diagnosis and treated in nine Hungarian centres. Most children belonged to the Hungarian (Caucasian) population, although it is likely that approximately 5% were of Gypsy origin (estimate based on state population statistics). Informed consent was requested from the parents of patients. The study was approved by the Ethics Committee of the Hungarian Medical Research Council.
In most cases, DNA was extracted from peripheral blood taken in 2003 and 2004 in haematologic remission (n ¼ 276). From patients who died before our sample collection period, DNA was obtained from old bone marrow smears (n ¼ 15, prepared at diagnosis or in remission) available at two centres. We extracted genomic DNA from blood using the QIAmp Blood DNA Maxi kit (QIAGEN GmbH, Hilden, Germany), and from smears with the HighPure PCR Template Preparation kit (Roche Diagnostics GmbH, Roche Applied Science, Mannheim, Germany) according to the manufacturers' instructions.
In order to have a highly homogenous therapy group, only patients treated on low/standard-risk and medium-risk arms of the ALL Berlin-Münster-Frankfurt 90 and 95 study protocols were enrolled in the present study. 17, 34 We assessed the adverse effects occurring during the initial 6-to 8-month-long combined 'intensive' chemotherapy phase. This phase consisted of the following five parts: induction, intensification, consolidation, reinduction and re-intensification. The whole regimen includes repeated doses of intravenous vincristine, L-asparaginase, daunorubicin, doxorubicin, MTX, cyclophosphamide, cytosine arabinoside, oral prednisone, dexamethasone, mercaptopurine, thioguanine and intrathecal MTX. The protocol in low-risk and mediumrisk arms differed only in the number of anthracycline doses. Increased number of intrathecal MTX doses was administered to patients with meningeal leukaemic infiltration. The intensive phase of therapy was not altered between the ALL Berlin-Münster-Frankfurt 90 and 95 protocols; changes were rather made in the rules for classification of patients into risk groups, regarding the oral maintenance therapy and in the criteria of adverse effects indicating interruption and delay of therapy. There was only one modification affecting the chemotherapy agents in the intensive phase: between 1996 and 1999 the intensification phase was shortened (see Supplementary Table S1 for detailed description of the chemotherapy protocol).
After exclusions, 275 patients were enrolled for analysis. Patients were classified as having suffered acute, toxic encephalopathy in case of the occurrence of at least one acute-onset CNS symptom graded III or above according to CTCAE 3.0 criteria. Data regarding hypoglycaemia, electrolyte disturbances, intracranial vascular events, meningeal leukaemic infiltration, signs of liver failure, renal failure, comedication with neurotoxic pharmaceutics, severe hypertension, circulatory or respiratory failure due to any other severe states or diseases, as well as epilepsy or seizures preceding the diagnosis of ALL were searched within the files of these children. Patients whose acute CNS symptoms were associated with any such primary causes were not classified into the 'toxic encephalopathy' group.
MTX concentrations were measured in the CSF as part of a pharmacokinetic study performed earlier at one of the participating centres (2nd Department of Paediatrics, Semmelweis University, Budapest, Hungary) in the early 1990s. At the end of each 24-h-long MTX infusion in the consolidation therapy phase, a lumbar puncture was routinely performed in order to administer intrathecal chemotherapy. A total of 1-5 ml of CSF was taken before the injection of the drug. In our study population, 124 CSF MTX concentration data were available from 40 patients. Values of all four MTX courses were available in case of 20 patients.
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Laboratory methods
The ABCB1 3435T4C, 2677G/T,A and 1236T4C genotypes were determined by a single base extension method based on the procedure published by Gwee et al., 35 with several minor alterations. ABCG2 34G4A and 421C4A genotyping was performed using the LightCycler (Roche Diagnostics) allelic discrimination system. 36 Detailed description of these procedures can be found in the online Supplementary material. CSF MTX concentrations were measured by highperformance liquid chromatography; the method was described in details earlier. 37 
Statistical analysis
Genotype data were analysed as dichotomous variables: homozygotes for the more frequent allele versus those harbouring at least one variant allele. In order to assess the association of the frequency of encephalopathy episodes with genotype, we used unadjusted and multi-adjusted generalized linear model procedures with logistic design. In uni-and multi-adjusted models, 95% confidence intervals were calculated. The multi-adjusted models included the following potential confounders: hospital, chemotherapy protocol, total anthracycline dose, sex, age and the time span of therapy. Interaction between genes was evaluated on both additive and multiplicative scales. 38 When evaluating CSF MTX concentrations and genotype, the Mann-Whitney U-test was applied to the whole data set. We also performed mixed analysis of variance of the repeated drug level data. Mixed models handle missing data for one patient, without removing all of the observations from that patient. 39 Analyses were performed using the SPSS 13.0 (SPSS Inc., Chicago, IL, USA) and SAS 9.1 (SAS Institute) software packages.
